Literature DB >> 18980539

Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei.

Sara K Bondi1, Joanna B Goldberg.   

Abstract

Burkholderia mallei and Burkholderia pseudomallei are Gram-negative, rod-shaped bacteria, and are the causative agents of the diseases glanders and melioidosis, respectively. These bacteria have been recognized as important pathogens for over 100 years, yet a relative dearth of available information exists regarding their virulence determinants and immunopathology. Infection with either of these bacteria presents with nonspecific symptoms and can be either acute or chronic, impeding rapid diagnosis. The lack of a vaccine for either bacterium also makes them potential candidates for bioweaponization. Together with their high rate of infectivity via aerosols and resistance to many common antibiotics, both bacteria have been classified as category B priority pathogens by the US NIH and US CDC, which has spurred a dramatic increase in interest in these microorganisms. Attempts have been made to develop vaccines for these infections, which would not only benefit military personnel, a group most likely to be targeted in an intentional release, but also individuals who may come in contact with glanders-infected animals or live in areas where melioidosis is endemic. This review highlights some recent attempts of vaccine development for these infections and the strategies used to improve the efficacy of vaccine approaches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18980539      PMCID: PMC2680498          DOI: 10.1586/14760584.7.9.1357

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  64 in total

Review 1.  Antibody regulation of Tcell immunity: implications for vaccine strategies against intracellular pathogens.

Authors:  Joseph U Igietseme; Francis O Eko; Qing He; Carolyn M Black
Journal:  Expert Rev Vaccines       Date:  2004-02       Impact factor: 5.217

Review 2.  Genome-derived vaccines.

Authors:  Anne S De Groot; Rino Rappuoli
Journal:  Expert Rev Vaccines       Date:  2004-02       Impact factor: 5.217

3.  Identification of a Burkholderia mallei polysaccharide gene cluster by subtractive hybridization and demonstration that the encoded capsule is an essential virulence determinant.

Authors:  D DeShazer; D M Waag; D L Fritz; D E Woods
Journal:  Microb Pathog       Date:  2001-05       Impact factor: 3.738

4.  Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis.

Authors:  F N Lauw; A J Simpson; J M Prins; M D Smith; M Kurimoto; S J van Deventer; P Speelman; W Chaowagul; N J White; T van der Poll
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

5.  Detection of bacterial virulence genes by subtractive hybridization: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant.

Authors:  S L Reckseidler; D DeShazer; P A Sokol; D E Woods
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

6.  Burkholderia pseudomallei kills the nematode Caenorhabditis elegans using an endotoxin-mediated paralysis.

Authors:  A L O'Quinn; E M Wiegand; J A Jeddeloh
Journal:  Cell Microbiol       Date:  2001-06       Impact factor: 3.715

7.  Characterization of experimental equine glanders.

Authors:  Jose Lopez; John Copps; Catherine Wilhelmsen; Richard Moore; Julie Kubay; Marcel St-Jacques; Stacey Halayko; Christiaan Kranendonk; Shannon Toback; David DeShazer; David L Fritz; Marina Tom; Donald E Woods
Journal:  Microbes Infect       Date:  2003-10       Impact factor: 2.700

Review 8.  Melioidosis.

Authors:  N J White
Journal:  Lancet       Date:  2003-05-17       Impact factor: 79.321

9.  Intensity of rainfall and severity of melioidosis, Australia.

Authors:  Bart J Currie; Susan P Jacups
Journal:  Emerg Infect Dis       Date:  2003-12       Impact factor: 6.883

10.  Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis.

Authors:  Mark P Stevens; Ashraful Haque; Timothy Atkins; Jim Hill; Michael W Wood; Anna Easton; Michelle Nelson; Cindy Underwood-Fowler; Richard W Titball; Gregory J Bancroft; Edouard E Galyov
Journal:  Microbiology (Reading)       Date:  2004-08       Impact factor: 2.777

View more
  32 in total

1.  Cloning, purification, crystallization and preliminary X-ray analysis of the Burkholderia pseudomallei L1 ribosomal protein.

Authors:  Abd Ghani Abd Aziz; Sergey N Ruzheinikov; Svetlana E Sedelnikova; Rahmah Mohamed; Sheila Nathan; Patrick J Baker; David W Rice
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-02-22

2.  Recent Advances in Burkholderia mallei and B. pseudomallei Research.

Authors:  Christopher L Hatcher; Laura A Muruato; Alfredo G Torres
Journal:  Curr Trop Med Rep       Date:  2015-06

3.  Burkholderia mallei CLH001 Attenuated Vaccine Strain Is Immunogenic and Protects against Acute Respiratory Glanders.

Authors:  Christopher L Hatcher; Tiffany M Mott; Laura A Muruato; Elena Sbrana; Alfredo G Torres
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

4.  Antibodies against In Vivo-Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Shawn M Zimmerman; Jeremy S Dyke; Tomislav P Jelesijevic; Frank Michel; Eric R Lafontaine; Robert J Hogan
Journal:  Infect Immun       Date:  2017-07-19       Impact factor: 3.441

5.  Low-dose exposure of C57BL/6 mice to burkholderia pseudomallei mimics chronic human melioidosis.

Authors:  Laura Conejero; Natasha Patel; Melanie de Reynal; Sara Oberdorf; Joanne Prior; Philip L Felgner; Richard W Titball; Francisco J Salguero; Gregory J Bancroft
Journal:  Am J Pathol       Date:  2011-05-05       Impact factor: 4.307

6.  Revised structures for the predominant O-polysaccharides expressed by Burkholderia pseudomallei and Burkholderia mallei.

Authors:  Christian Heiss; Mary N Burtnick; Rosemary A Roberts; Ian Black; Parastoo Azadi; Paul J Brett
Journal:  Carbohydr Res       Date:  2013-08-24       Impact factor: 2.104

7.  Genetic and biochemical map for the biosynthesis of occidiofungin, an antifungal produced by Burkholderia contaminans strain MS14.

Authors:  Ganyu Gu; Leif Smith; Aixin Liu; Shi-En Lu
Journal:  Appl Environ Microbiol       Date:  2011-07-08       Impact factor: 4.792

8.  Burkholderia thailandensis oacA mutants facilitate the expression of Burkholderia mallei-like O polysaccharides.

Authors:  Paul J Brett; Mary N Burtnick; Christian Heiss; Parastoo Azadi; David DeShazer; Donald E Woods; Frank C Gherardini
Journal:  Infect Immun       Date:  2010-11-29       Impact factor: 3.441

9.  In Vitro and In Vivo studies of monoclonal antibodies with prominent bactericidal activity against Burkholderia pseudomallei and Burkholderia mallei.

Authors:  Shimin Zhang; Shaw-Huey Feng; Bingjie Li; Hyung-Yong Kim; Joe Rodriguez; Shien Tsai; Shyh-Ching Lo
Journal:  Clin Vaccine Immunol       Date:  2011-03-30

10.  A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection.

Authors:  Wildaliz Nieves; Saja Asakrah; Omar Qazi; Katherine A Brown; Jonathan Kurtz; David P Aucoin; James B McLachlan; Chad J Roy; Lisa A Morici
Journal:  Vaccine       Date:  2011-08-24       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.